October 26, 2026

Company name: Taiko Pharmaceutical Co., Ltd.
Representative: Takashi Shibata
President and CEO
Securities code: 4574 (TSE Prime Market)
Contact: Toru Nakajo
VP, Corporate Division,
Accounting Department
(Email: ir@seirogan.co.jp)

Notice Concerning Approval of a Market Division Change to the Standard Market and Withdrawal of the Plan to Comply with the Continued Listing Criteria for the Prime Market

Taiko Pharmaceutical Co., Ltd. (the "Company") announced that it received approval today from Tokyo Stock Exchange, Inc. (the "TSE") to change its market division to the Standard Market. Accordingly, the Company's shares will be transferred from the Prime Market to the Standard Market of the TSE effective November 2, 2026, as described below.

1. Reason for Change to the Standard Market

As announced in "Notice Concerning Application for a Market Division Change to the Tokyo Stock Exchange Standard Market" dated August 25, 2026, the Company has considered changing its market division, taking into account its current corporate scale, business environment, and future growth strategy, from the perspective of its long-term management strategy and the maximization of shareholder value.

As a result, the Company determined that the Standard Market was a more appropriate market division for its current corporate scale and stage of growth, and that pursuing sustainable growth and enhancing medium- to long-term corporate value in the Standard Market would contribute to the interests of all stakeholders, including shareholders. For these reasons, it applied for a market division change.

Even after the market division change, there will be no change to the Company's basic policy of pursuing sustainable growth and enhancing medium- to long-term corporate value. The Company will continue to strive to enhance its corporate value to meet the expectations of stakeholders, including shareholders.

2. Withdrawal of the Plan to Comply with the Continued Listing Criteria for the Prime Market

The Company submitted and announced the "Notice Concerning Plan to Comply with the Continued Listing Criteria (Entering Improvement Period)" on March 24, 2026, and has been implementing various measures aimed at achieving compliance with the continued listing criteria for the Prime Market. However, following approval of its market division change to the Standard Market, the Company is withdrawing the plan effective today.

3. Scheduled Date of the Market Division Change to the Standard Market

The scheduled date of the market division change to the Standard Market is November 2, 2026. From that date, the Company's shares will be traded on the Standard Market.